Docs value details, says PhRMA survey

Share this article:
A PhRMA-sponsored survey found that nearly eight in 10 US physicians see drug companies and their sales reps as useful sources of information on prescription drugs.

The telephone survey of 500-plus American Medical Association members, conducted by KRC Research, “found that physicians consider a broad range of factors in making their prescribing decisions,” with just under 70% using info provided by company reps and over 80% saying they took into consideration the patient's insurance factors, including formulary and prior authorization requirements.

More than 90% of respondents said their interactions with reps allow them to learn about new indications, potential side effects and emerging risks and benefits of medicines, and 84% said their interactions with reps let them provide feedback to companies about their experiences with specific medicines. Most found info from reps to be up to date and timely (94%), useful (92%) and reliable (84%).

Asked about company-sponsored peer education programs, almost 90% said such information was up to date, useful and reliable. Ninety-four percent said the programs strengthened their ability to care for patients.

PhRMA's Kate Connor suggested that the results offer a “second opinion” on the value of industry-physician interaction.

“To suggest that physicians' treatment decisions would be compromised by these interactions is an insult to their profession and, indeed, to the integrity of the FDA-regulated information that biopharmaceutical research companies provide,” Connor blogged, “data that reflect many years and billions of dollars worth of research. It is only appropriate that the companies that develop the data are the ones with the expertise to disseminate and discuss it.”
Share this article:

Email Newsletters

More in News

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.

GSK second-quarter sales disappoint

GSK second-quarter sales disappoint

Executives urge analysts to focus on the company's long-term potential.

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union